VEA
RXRX icon

Virtus ETF Advisers’s Recursion Pharmaceuticals RXRX Stock Holding History

Virtus ETF Advisers’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,185
Closed -$68.9K – 730
2024
Q4 		$68.9K Buy
10,185
+422
+4% +$2.84K 0.03% 386
2024
Q3 		$64.3K Buy
9,763
+173
+2% +$1.24K 0.03% 436
2024
Q2 		$71.9K Buy
9,590
+497
+5% +$4.33K 0.04% 429
2024
Q1 		$90.7K Sell
9,093
-622
-6% -$6.93K 0.05% 380
2023
Q4 		$95.8K Sell
9,715
-317
-3% -$2.26K 0.06% 379
2023
Q3 		$76.7K Sell
10,032
-996
-9% -$9.94K 0.05% 367
2023
Q2 		$82.4K Sell
11,028
-57
-0.5% -$399 0.05% 426
2023
Q1 		$73.9K Sell
11,085
-4,257
-28% -$33.8K 0.04% 397
2022
Q4 		$118K Sell
15,342
-1,505
-9% -$14.8K 0.06% 421
2022
Q3 		$179K Buy
16,847
+121
+0.7% +$1.23K 0.07% 330
2022
Q2 		$136K Buy
16,726
+8,405
+101% +$56.2K 0.05% 337
2022
Q1 		$60K Sell
8,321
-500
-6% -$5.31K 0.03% 359
2021
Q4 		$151K Buy
+8,821
New +$166K 0.06% 346

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Virtus ETF Advisers's RXRX Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Recursion Pharmaceuticals (RXRX) in Q1 2025, closing a stake of 10,185 shares — an estimated $68.9K sold.

Virtus ETF Advisers first reported a position in RXRX in Q4 2021 and held it in 13 quarters. The position peaked at $179K in Q3 2022. 336 funds tracked by Wall St. Rank hold RXRX as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Recursion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 10,185 Recursion Pharmaceuticals shares in Q1 2025, an estimated $68.9K.
  • Virtus ETF Advisers first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 13 quarters.
  • Virtus ETF Advisers's Recursion Pharmaceuticals position peaked at $179K in Q3 2022.
  • 336 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.